Addendum

Acalabrutinib (mantle cell lymphoma; combination with bendamustine and rituximab) – Addendum to Project A25-89

Report documents

Indication:

Adults with previously untreated mantle cell lymphoma who are not eligible for autologous stem cell transplant

Result of dossier assessment:

Patients for whom bendamustine + rituximab is a suitable individualized treatment: unchanged after addendum: hint of a lesser benefit
Patients for whom bendamustine + rituximab is not a suitable individualized treatment: unchanged after addendum: added benefit not proven

18-12-2025 A G-BA decision was published.
G-BA documents on this decision

Project no.: A25-143
Commission: Commission awarded on 11.11.2025 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Cancer
Note: If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
DOI: https://doi.org/10.60584/A25-143_en

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.